TAE Life Sciences to Sponsor Industry Theater Session on the Future of Precision Oncology at 2022 ASTRO Annual Meeting

Miami Cancer Institute and UT Health Houston join TAE Life Sciences to discuss the future of biologically targeted radiotherapy

FOOTHILL RANCH, Calif.--()--TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry Education session focused on the future of biologically targeted radiotherapy at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 22-26, 2022.

The Industry Theater session, “A Glimpse into the Future: Biologically Targeted Radiotherapy” will feature presentations by Sunil Krishnan, M.B.B.S., M.D., Professor, Radiation Oncology, UT Health Houston, Minesh P. Mehta, MD., Deputy Director & Chief of Radiation Oncology, Miami Cancer Institute and Art Raitano, Senior Director Protein Sciences, TAE Life Sciences.

Session Title: A Glimpse into the Future: Biologically Targeted Radiotherapy
Location: Theater 2
Date: Sunday, October 23, 4:00 – 5:00 PM

BNCT is one of the most exciting developments in radiation therapy, and yet it remains inadequately explored in the clinic due to technological and pharmacological limitations. The good news is that we are looking at an extremely bright future with a variety of novel technological solutions that allow in-hospital accommodation of these devices in typical radiotherapy clinics,” said Minesh P. Mehta, M.D., Deputy Director & Chief of Radiation Oncology, Miami Cancer Institute. “The utilization of targeted drugs for a variety of malignancies which allow the enrichment of boron concentration in tumors might represent the ultimate frontier for enhancing BNCT into mainstream radiotherapy.”

I believe a resurgence of interest in BNCT via technological advances in the design of accelerator-based BNCT platforms and future development of next-generation boron therapeutics will enable the advancement of genuine biologically targeted therapy,” said Sunil Krishnan, Professor, Radiation Oncology, UT Health Houston.

In addition, TAE Life Sciences will be presenting the following posters:

Poster Title: Development of New Targeted Boronated Small Molecule Drugs for Boron Neutron Capture Therapy (BNCT)
Poster Number: 3170
Presenting Author: Art Raitano, Senior Director Protein Sciences, TAE Life Sciences
Date: Monday, October 24, 5:00 PM

Poster Title: Development of a Clinical Neutron Source for Boron Neutron Capture Therapy
Poster Number: 3200
Presenting Author: Charles Lee, Director of Clinical Development, TAE Life Sciences
Date: Wednesday, October 26, 12:30 PM

About BNCT

BNCT is a combination treatment based on the reaction that occurs when a non-toxic compound containing boron-10 is irradiated with a low-energy neutron beam. BNCT differs radically from other radiation therapy and shows promise in becoming the next-generation cancer treatment. Research has shown BNCT has the capability of killing cancer cells that are resistant to traditional radiation therapy with limited harm to healthy tissue. Current advances in both neutron radiation technology and medicinal boron drug targeting are enabling BNCT’s potential to improve patient care while also improving treatment economics. To date, approximately 2,000 patients have been treated with BNCT at research sites worldwide.

About TAE Life Sciences

TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TLS is developing the next generation targeted boron drugs and low-energy accelerator-based neutron source – optimized for an in-hospital BNCT program that can one day treat patients with the most aggressive and recurrent cancers. We have assembled a world-class, cross-functional team of clinicians, radiation oncologists, physicists, and other researchers to enable us to bring our technology to cancer patients who need it most. TLS’s target drugs and neutron radiation system are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at www.taelifesciences.com.

Contacts

MacDougall
Holly Hancock
HHancock@macdougall.bio
(781) 235-3060

Release Summary

TAE Life Sciences will sponsor an Industry Education session focused on the future of biologically targeted radiotherapy at ASTRO 2022.

Contacts

MacDougall
Holly Hancock
HHancock@macdougall.bio
(781) 235-3060